Evidence & Research Status
A plain accounting of which GLP-1 health benefits are FDA-approved for a named branded drug, which are still being studied, and which trials have already failed — so the difference between “approved,” “promising,” and “unproven” doesn’t get lost.
Evidence Level reflects the general state of published research across this drug class and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
Interest in GLP-1 health benefits has moved well past weight management and blood sugar. Over the past two years, the same drug class has picked up FDA approvals for heart and kidney outcomes, and researchers are actively investigating effects on the brain, liver, and addiction circuitry. Some of that research has succeeded. Some of it has already failed. This article separates the two, and separates both from what PTW’s research-use-only compounds are and are not evaluated for.
Three different things get called “GLP-1 benefits”
The first is an FDA-approved indication for a specific branded drug — Wegovy, Ozempic, Zepbound, or Mounjaro — backed by a completed Phase 3 trial and a label change. The second is an investigational use: a signal from an early trial, an observational study, or animal research that hasn’t reached approval and may never. The third is what applies to a compounded or research-grade peptide — including everything sold on this site — which is not the approved branded drug, has not been evaluated by the FDA for any indication, and is sold strictly for laboratory and research use. Conflating these three is the single most common way GLP-1 coverage goes wrong, so this article keeps them in separate sections.
What’s actually FDA-approved today
Beyond weight management and type 2 diabetes, four approvals now exist for named branded drugs:
Cardiovascular risk reduction. Wegovy (semaglutide) is approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease, based on the SELECT trial. Lilly’s Mounjaro (tirzepatide) received a similar FDA expansion for reducing cardiovascular event risk (FiercePharma).
Chronic kidney disease. Ozempic (semaglutide) is FDA-approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, the only GLP-1 with this approval. The supporting FLOW trial reported a 24% reduction in kidney disease progression and a 5% reduction in cardiovascular death (BioSpace).
Obstructive sleep apnea. Zepbound (tirzepatide) is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, the first drug approved for this indication.
MASH (liver disease). Wegovy received accelerated approval for metabolic dysfunction-associated steatohepatitis (MASH), a serious fat-driven liver disease. A study published in the New England Journal of Medicine found Wegovy improved or stabilized liver health in 63% of MASH participants (AARP summary).
All four are approvals for a specific prescription drug, prescribed and monitored by a physician. None of them are an approval, indication, or endorsement for any research-use-only compound, including the ones sold here.
What’s under active investigation — including a trial that failed
Alzheimer’s disease — negative result. The Phase 3 EVOKE and EVOKE+ trials tested oral semaglutide in more than 3,800 people with mild cognitive impairment or early Alzheimer’s. Full results presented in March 2026 showed no benefit over placebo on the primary endpoint (cognitive and functional decline) at two years. Researchers did observe reductions of roughly 10% in several Alzheimer’s-related biomarkers, but this did not translate into a measurable clinical benefit (NeurologyLive, The Lancet). This is one of the more rigorous negative results in the GLP-1 research literature and is a useful check on the “cures everything” framing this drug class sometimes gets.
Substance use disorders. Observational data from Washington University found GLP-1 use was associated with lower rates of alcohol, nicotine, cannabis, cocaine, and opioid use disorders, plus fewer overdoses and drug-related hospitalizations, compared to other medications (ScienceDaily). A systematic review of the field found the evidence base still thin — 41 studies total, 35 of them preclinical and only 6 in human clinical trials (PMC systematic review). Promising mechanism, early-stage human evidence.
Biological aging and lifespan. PTW’s Research Library already covers this in depth — see GLP-1 Receptor Agonists and Biological Aging and the semaglutide-specific mouse lifespan data. Short version: promising signals in animal models and epigenetic-clock studies, nothing established in human lifespan or healthspan.
Cancer risk, mood, joint health, and mortality. Each has its own dedicated, evidence-graded article: GLP-1 Cancer Risk, GLP-1 Mood Research, Semaglutide & Knee Osteoarthritis, and the SURMOUNT-MMO mortality trial. None of these are settled indications; all are active research areas with early-to-moderate evidence.
| Area | Evidence stage | Key trial/study | Status |
|---|---|---|---|
| Weight management, type 2 diabetes | FDA-approved (branded drugs) | Multiple Phase 3 programs | Approved indication |
| Cardiovascular risk reduction | FDA-approved (Wegovy, Mounjaro) | SELECT | Approved indication |
| Chronic kidney disease | FDA-approved (Ozempic) | FLOW | Approved indication |
| Obstructive sleep apnea | FDA-approved (Zepbound) | SURMOUNT-OSA | Approved indication |
| MASH / liver disease | FDA-approved, accelerated (Wegovy) | NEJM MASH trial | Approved indication, confirmatory data pending |
| Alzheimer’s / cognition | Phase 3 completed | EVOKE, EVOKE+ | Failed primary endpoint — not supported |
| Substance use disorders | Observational + limited clinical | WashU cohort study | Early signal, not established |
| Biological aging / lifespan | Preclinical + biomarker | Mouse lifespan study, epigenetic clock studies | Not established in humans |
| Cancer risk association | Observational, pooled | 78-study meta-analysis | Association only, not causal |
Is this a “longevity drug”? Not yet, by the evidence
The honest read of the table above: this drug class has real, FDA-recognized benefits outside weight and blood sugar — heart, kidney, sleep apnea, liver — each backed by a completed trial and a label change for a named drug. It also has a growing list of investigational leads, several of which are compelling mechanistically. But “longevity drug” implies a demonstrated effect on human aging or lifespan, and that hasn’t been shown — the EVOKE trials just demonstrated that a plausible-sounding mechanism (reduced neuroinflammation) doesn’t guarantee a clinical result. The right framing for a researcher is: some benefits are approved and drug-specific, some are promising and unproven, and the gap between those two categories is exactly what ongoing trials are trying to close.
What this means for research-grade GLP-1 compounds
Every approval and finding described above applies to a specific branded, physician-prescribed pharmaceutical studied in a formal clinical trial. It does not apply to compounded or research-use-only peptides, including semaglutide, tirzepatide, retatrutide, or cagrilintide sold on this site. These products are not the approved drug, have not been evaluated by the FDA for any use, and are sold exclusively for laboratory and research purposes. Anyone with a personal health condition — cardiovascular, renal, metabolic, or otherwise — should discuss treatment options with a licensed physician rather than drawing conclusions from research literature about a different, regulated product.
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.